We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Read MoreHide Full Article
Key Takeaways
Merck won FDA approval for Lipfendra, the first oral PCSK9 inhibitor to lower LDL cholesterol.
MRK said phase III studies showed Lipfendra cut LDL cholesterol by 56% and 59% versus placebo.
Merck plans to launch Lipfendra at a $315 monthly list price in the coming weeks.
Shares of Merck (MRK - Free Report) rose more than 3% on Thursday after the company announced that the FDA approved enlicitide as the first oral PCSK9 inhibitor to reduce low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) in adults with hypercholesterolemia (high cholesterol). The drug will be marketed under the brand name Lipfendra.
The agency’s approval also covers patients with heterozygous familial hypercholesterolemia (HeFH), an inherited condition in which a person receives a mutated gene associated with high cholesterol from one parent.
The approval is supported by data from two phase III studies, CORALreef Lipids and CORALreef HeFH, which evaluated a 20 mg once-daily dose of the drug over 24 weeks. While data from the CORALreef Lipids study showed that Lipfendra reduced LDL-C by 56% versus placebo in patients with hypercholesterolemia, the CORALreef HeFH study demonstrated a 59% reduction compared to placebo in HeFH patients.
The drug is expected to launch in the coming weeks at a list price of $315 per month, significantly lower than the list prices of currently available PCSK9 injectables, including Amgen’s (AMGN - Free Report) Repatha and Novartis’ (NVS - Free Report) Leqvio. This competitive pricing was not unexpected, as Merck had previously indicated that it intended to position Lipfendra as an affordable treatment under its agreement with the U.S. government to expand access to medicines and lower costs for citizens. Although the drug's commercial success will ultimately depend on Merck's net pricing strategy and payer adoption, its oral formulation could provide a meaningful competitive advantage over injectable PCSK9 therapies.
MRK’s Stock Performance
Year to date, the company’s shares have risen 21% compared with the industry’s 9% growth.
Image Source: Zacks Investment Research
More on Merck’s Lipfendra
The drug is currently being evaluated in a late-stage cardiovascular outcomes study to determine whether it can reduce the risk of major adverse cardiovascular events, as well as cardiovascular morbidity and mortality.
Lipfendra could become an important long-term growth driver for Merck. As the first once-daily oral PCSK9 inhibitor, the drug has the potential to expand the use of this class by offering a convenient alternative to injectable therapies, potentially improving patient uptake and adherence. If successful, Lipfendra could emerge as a meaningful revenue contributor and help diversify Merck's growth drivers as the company prepares for the loss of exclusivity for its blockbuster cancer therapy, Keytruda, later this decade.
View the Zacks #1 Rank List
Image: Bigstock
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Key Takeaways
Shares of Merck (MRK - Free Report) rose more than 3% on Thursday after the company announced that the FDA approved enlicitide as the first oral PCSK9 inhibitor to reduce low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) in adults with hypercholesterolemia (high cholesterol). The drug will be marketed under the brand name Lipfendra.
The agency’s approval also covers patients with heterozygous familial hypercholesterolemia (HeFH), an inherited condition in which a person receives a mutated gene associated with high cholesterol from one parent.
The approval is supported by data from two phase III studies, CORALreef Lipids and CORALreef HeFH, which evaluated a 20 mg once-daily dose of the drug over 24 weeks. While data from the CORALreef Lipids study showed that Lipfendra reduced LDL-C by 56% versus placebo in patients with hypercholesterolemia, the CORALreef HeFH study demonstrated a 59% reduction compared to placebo in HeFH patients.
The drug is expected to launch in the coming weeks at a list price of $315 per month, significantly lower than the list prices of currently available PCSK9 injectables, including Amgen’s (AMGN - Free Report) Repatha and Novartis’ (NVS - Free Report) Leqvio. This competitive pricing was not unexpected, as Merck had previously indicated that it intended to position Lipfendra as an affordable treatment under its agreement with the U.S. government to expand access to medicines and lower costs for citizens. Although the drug's commercial success will ultimately depend on Merck's net pricing strategy and payer adoption, its oral formulation could provide a meaningful competitive advantage over injectable PCSK9 therapies.
MRK’s Stock Performance
Year to date, the company’s shares have risen 21% compared with the industry’s 9% growth.
Image Source: Zacks Investment Research
More on Merck’s Lipfendra
The drug is currently being evaluated in a late-stage cardiovascular outcomes study to determine whether it can reduce the risk of major adverse cardiovascular events, as well as cardiovascular morbidity and mortality.
Lipfendra could become an important long-term growth driver for Merck. As the first once-daily oral PCSK9 inhibitor, the drug has the potential to expand the use of this class by offering a convenient alternative to injectable therapies, potentially improving patient uptake and adherence. If successful, Lipfendra could emerge as a meaningful revenue contributor and help diversify Merck's growth drivers as the company prepares for the loss of exclusivity for its blockbuster cancer therapy, Keytruda, later this decade.
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
MRK’s Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.